查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750696

日本醫藥合約開發與製造組織市場：市場規模、佔有率、趨勢分析（按產品、工作流程、應用、服務和最終用途）、細分市場預測（2025-2030 年）

Japan Contract Development & Manufacturing Organizations Market Size, Share & Trends Analysis Report By Product, By Workflow, By Application, By Service, By End Use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 127 Pages | 商品交期: 2-10個工作天內

價格

日本醫藥合約開發與製造組織市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，日本醫藥合約開發和製造組織市場預計到2030年將達到207.6億美元，2025年至2030年期間的複合年成長率為7.77%。

生物製藥需求成長、疾病負擔加重、老年人口成長是主要成長要素。預測期內，各合約開發和製造組織 (CDMO) 對其設施和服務擴建的投資不斷增加，可能會提振市場。

此外，製藥公司不斷增加的研發投入也推動了市場成長。隨著製藥公司加大研發投入，他們可能會尋求外部專業知識和資源來加速藥物開發進程。 CDMO 提供藥物開發、生產和測試方面的專業服務，對於希望委託方面研發活動的製藥公司來說，它們無疑是寶貴的合作夥伴。目前已有多家公司投資醫藥研發活動。例如，藥明康德於 2022 年 3 月推出了四環黴素相容於自惰性腺病毒 (TESSA) 技術，旨在加速用於細胞和基因治療的藥物用腺結合病毒的生產。

製藥業中製藥公司外包服務的增加正在對日本市場產生重大影響。製藥公司外包的趨勢是由獲得對藥品成功開發和商業化至關重要的新技術的價值所驅動的，這導致了製藥業外包活動的增加。外包在製造方面具有顯著的優勢，包括提供專業知識、改善現金流管理以及降低投資風險。

值得注意的是，日本監管機構正在加速再生醫學和基因治療產品的核准。例如，《藥品和醫療設備法》（PMD法案）、《21世紀治癒法案》以及「優先藥物」（PRIME）計畫的通過，幫助日本改善了再生醫學的可及性。這些監管措施預計將促進日本再生醫學的開發和生產需求。

日本藥品合約開發與製造組織市場報告：重點

  • 2024年，原料藥(API) 佔據市場主導地位，市佔率達 81.14%。該領域的成長主要源於市場對競爭性藥物開發以及端到端合約開發與生產組織 (CDMO) 服務日益成長的需求。此外， 原料藥製造技術的進步、生物製藥行業的成長以及老年人口的成長也是推動該領域成長的主要因素。
  • 這是由於對生物相似藥、學名藥、再生療法等藥品的需求強勁。商用CDMO 可以透過提供知識、節省時間和成本效益來提供幫助。
  • 從應用角度來看，由於日本癌症發生率高，腫瘤學在2024年佔據了日本CDMO產業的主導地位。再生產品和病毒療法在癌症治療中的核准進一步推動了市場成長，而全球癌症患者數量的增加也進一步推動了該產業的發展。此外，醫藥研發投入的增加、專利到期以及對抗癌藥物和生物創新的需求也是推動腫瘤學產業成長的因素。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章：日本醫藥合約開發與製造組織市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 定價模式分析
  • 技術狀況
  • 經營模式分析
  • 法律規範
  • 臨床試驗數量分析（2024年）
    • 各階段臨床試驗總數（2024 年）
    • 按臨床實驗設計分類的臨床試驗總數（2024 年）
    • 按主要治療領域分類的臨床試驗總數（2024 年）
  • 日本醫藥品合約開發與製造組織市場的分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影響分析

第4章：日本醫藥合約開發與製造組織市場：按產品進行的估算與趨勢分析

  • 細分儀表板
  • 日本醫藥合約開發製造組織市場：依產品波動分析
  • 日本合約開發製造組織 (CDO) 市場規模及產品趨勢分析（2018-2030 年）
  • API
    • 種類
    • 合成方法
    • 藥物
    • 製造方法
  • 製藥
    • 依藥物類型
    • 按類型
    • 按分子

第5章：日本醫藥合約開發與製造組織市場：依工作流程估算與趨勢分析

  • 細分儀表板
  • 日本醫藥合約開發與製造組織市場：依工作流程的波動分析
  • 日本合約開發和製造組織 (CDO) 市場規模及趨勢分析（按工作流程）（2018-2030 年）
  • 臨床
  • 上市

第6章日本醫藥合約開發與製造組織市場：按應用的估計和趨勢分析

  • 細分儀表板
  • 日本醫藥合約開發與製造組織市場：依應用進行趨勢分析
  • 日本合約開發與製造組織 (CDO) 市場規模及應用趨勢分析（2018-2030 年）
  • 腫瘤學
  • 荷爾蒙
  • 青光眼
  • 心血管疾病
  • 糖尿病
  • 其他

第7章日本醫藥合約開發與製造組織市場：按服務分類的估計和趨勢分析

  • 細分儀表板
  • 日本醫藥合約開發與製造組織市場：按服務分類的波動分析
  • 日本合約開發製造組織 (CDO) 市場規模及服務趨勢分析（2018-2030 年）
  • 合約開發
  • 契約製造
  • 包裹
  • 品管與保證
    • 目視檢查
    • 其他
  • 其他

第8章：日本醫藥合約開發與製造組織市場：按最終用途的估計和趨勢分析

  • 細分儀表板
  • 日本醫藥合約開發與製造組織市場：依最終用途進行趨勢分析
  • 日本合約開發與製造組織 (CDO) 市場規模及趨勢分析（以最終用途）（2018-2030 年）
  • 製藥公司
  • 生技公司
  • 其他

第9章：日本藥品合約開發與製造組織市場：競爭格局

  • 市場參與企業分類
  • 各公司市場佔有率分析（2024年）
  • 公司簡介
Product Code: GVR-4-68039-985-5

Japan Contract Development & Manufacturing Organizations Market Growth & Trends:

The Japan contract development and manufacturing organizations market size is estimated to reach USD 20.76 billion by 2030, expanding at a CAGR of 7.77% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.

In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.

The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market. The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.

Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.

Japan Contract Development & Manufacturing Organizations Market Report Highlights:

  • The active pharmaceutical ingredient (API) segment dominated the market with a share of 81.14% in 2024. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and the increasing geriatric population are some of the key factors propelling segment growth
  • Based on workflow, the commercial segment held the largest market share in 2024, attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective.
  • Based on application, the oncology segment dominated the Japan CDMO industry in 2024, owing to the high cancer burden in the country. Approval of regenerative products and virotherapy for cancer treatment can further support market growth and the segment is further driven by increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology segment growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Estimates and forecasts timeline.
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Bottom Up Approach (Model 2)
    • 1.7.3. Value Chain Based Approach (Model 3)
    • 1.7.4. Multivariate Analysis (Model 4)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Japan Contract Development and Manufacturing Organizations Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Demand for Biopharmaceutical Drugs in Japan
      • 3.2.1.2. High Geriatric Population And Growing Disease Burden in Japan
      • 3.2.1.3. Low Cost Associated with Outsourcing Drug Manufacturing and Development Services
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited Outsourcing Opted by Big Pharma Companies
      • 3.2.2.2. Quality Issues While Outsourcing
  • 3.3. Pricing Model Analysis
  • 3.4. Technology Landscape
  • 3.5. Business Model Analysis
  • 3.6. Regulatory Framework
  • 3.7. Clinical Trials Volume Analysis, 2024
    • 3.7.1. Total Number of Clinical Trials, by Phase (2024)
    • 3.7.2. Total Number of Clinical Trials, by Study Design (2024)
    • 3.7.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.8. Japan Contract Development and Manufacturing Organizations Market Analysis Tools
    • 3.8.1. Porter's Five Forces Analysis
    • 3.8.2. PESTEL Analysis
    • 3.8.3. COVID-19 Impact Analysis

Chapter 4. Japan Contract Development and Manufacturing Organizations Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Japan Contract Development and Manufacturing Organizations Market: Product Movement Analysis
  • 4.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. API
    • 4.4.1. API Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Type
      • 4.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API)
        • 4.4.2.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.2. Highly Potent Active Pharmaceutical Ingredient (HP-API)
        • 4.4.2.2.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.3. Antibody Drug Conjugate (ADC)
        • 4.4.2.3.1. Antibody Drug Conjugate (ADC) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.4. Others
        • 4.4.2.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Synthesis
      • 4.4.3.1. Synthetic
        • 4.4.3.1.1. Synthetic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 4.4.3.1.2. Solid
          • 4.4.3.1.2.1. Solid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 4.4.3.1.3. Liquid
          • 4.4.3.1.3.1. Liquid Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.3.2. Biotech
        • 4.4.3.2.1. Biotech Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Drug
      • 4.4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.4.2. Innovative
        • 4.4.4.2.1. Innovative Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.4.3. Generics
        • 4.4.4.3.1. Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Manufacturing
      • 4.4.5.1. Continuous manufacturing
        • 4.4.5.1.1. Continuous Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.5.2. Batch manufacturing
        • 4.4.5.2.1. Batch Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Drug Product
    • 4.5.1. By Drug Type
      • 4.5.1.1. Oral Solid Dose
        • 4.5.1.1.1. Oral Solid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.2. Semi-Solid Dose
        • 4.5.1.2.1. Semi-Solid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.3. Liquid Dose
        • 4.5.1.3.1. Liquid Dose Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.4. Others
        • 4.5.1.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. By Type
      • 4.5.2.1. Innovative
        • 4.5.2.1.1. Innovative Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.2. Generic
        • 4.5.2.2.1. Generic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. By Molecule
      • 4.5.3.1. Small Molecule
        • 4.5.3.1.1. Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.2. Large Molecule
        • 4.5.3.2.1. Large Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Japan Contract Development and Manufacturing Organizations Market: Workflow Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Japan Contract Development and Manufacturing Organizations Market: Workflow Movement Analysis
  • 5.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
  • 5.4. Clinical
    • 5.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Commercial
    • 5.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Japan Contract Development and Manufacturing Organizations Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Japan Contract Development and Manufacturing Organizations Market: Application Movement Analysis
  • 6.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Hormonal
    • 6.5.1. Hormonal Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Glaucoma
    • 6.6.1. Glaucoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Cardiovascular Diseases
    • 6.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Japan Contract Development and Manufacturing Organizations Market: Service Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Japan Contract Development and Manufacturing Organizations Market: Service Movement Analysis
  • 7.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 7.4. Contract Development
    • 7.4.1. Contract Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Contract Manufacturing
    • 7.5.1. Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Packaging
    • 7.6.1. Packaging Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Quality Control and Assurance
    • 7.7.1. Quality Control and Assurance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Visual Inspection
      • 7.7.2.1. Visual Inspection Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Others
      • 7.7.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Others
    • 7.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Japan Contract Development and Manufacturing Organizations Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Japan Contract Development and Manufacturing Organizations Market: End Use Movement Analysis
  • 8.3. Japan Contract Development and Manufacturing Organizations Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 8.4. Pharmaceutical Companies
    • 8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Biotechnology Companies
    • 8.5.1. Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Japan Contract Development and Manufacturing Organizations Market: Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Company Market Assessment Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. LabCorp
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Wuxi AppTec, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Lonza
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Recipharm AB
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Samsung Biologics
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Catalent, Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. CordenPharma International
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Cambrex Corporation
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Thermo Fisher Scientific, Inc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. FUJIFILM Diosynth Biotechnologies
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Sumitomo Chemical Company, Limited
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. CMIC HOLDINGS Co., LTD.
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. Bushu Pharmaceuticals Ltd.
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Nipro Corporation
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 Japan Contract Development and Manufacturing Organizations Market, By Product, 2018 - 2030 (USD Million)
  • Table 4 Japan Contract Development and Manufacturing Organizations Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 5 Japan Contract Development and Manufacturing Organizations Market, By Application, 2018 - 2030 (USD Million)
  • Table 6 Japan Contract Development and Manufacturing Organizations Market, Service, 2018 - 2030 (USD Million)
  • Table 7 Japan Contract Development and Manufacturing Organizations Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8 ADC Approvals in Japan
  • Table 9 Financial Performance
  • Table 10 Key company initiating service launches/upgrades
  • Table 11 Key companies initiating service launches/upgrades
  • Table 12 Key companies initiating partnerships
  • Table 13 Key companies initiating expansion
  • Table 14 Key companies initiating expansion

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market Research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Japan contract development and manufacturing organizations market segmentation
  • Fig. 7 Market driver analysis
  • Fig. 8 Market restraint relevance analysis
  • Fig. 9 Porter's five forces analysis
  • Fig. 10 PESTEL by SWOT analysis
  • Fig. 11 Regional marketplace: Key takeaways
  • Fig. 12 Japan synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 Japan solid market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Japan liquid market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Japan biotech market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Japan Traditional Active Pharmaceutical Ingredient (Traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Japan Highly Potent Active Pharmaceutical Ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Japan Antibody Drug Conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Japan innovative market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Japan generics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Japan continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Japan batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Japan oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Japan semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Japan liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Japan innovative market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Japan generics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Japan small molecule market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Japan large molecule market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Japan clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Japan commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Japan oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Japan hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Japan diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Japan contract development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Japan packaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan quality control and assurance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan visual inspection market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Japan others market estimates and forecasts, 2018 - 2030 (USD Million)